WARNING: This product is for research use only, not for human or veterinary use.
MedKoo CAT#: 326684
CAS#: 1352792-74-5
Description: Verinurad, also known as RDEA3170, is an organic anion transporter URAT1 (SLC22A12) inhibitor, is being developed by Ardea Biosciences (a subsidiary of AstraZeneca) for the treatment of gout and hyperuricaemia.
MedKoo Cat#: 326684
Name: Verinurad
CAS#: 1352792-74-5
Chemical Formula: C20H16N2O2S
Exact Mass: 348.0932
Molecular Weight: 348.42
Elemental Analysis: C, 68.95; H, 4.63; N, 8.04; O, 9.18; S, 9.20
Synonym: RDEA3170; RDEA-3170; RDEA 3170; Verinurad
IUPAC/Chemical Name: 2-((3-(4-cyanonaphthalen-1-yl)pyridin-4-yl)thio)-2-methylpropanoic acid
InChi Key: YYBOLPLTQDKXPM-UHFFFAOYSA-N
InChi Code: InChI=1S/C20H16N2O2S/c1-20(2,19(23)24)25-18-9-10-22-12-17(18)16-8-7-13(11-21)14-5-3-4-6-15(14)16/h3-10,12H,1-2H3,(H,23,24)
SMILES Code: CC(C)(SC1=C(C2=C3C=CC=CC3=C(C#N)C=C2)C=NC=C1)C(O)=O
1: Diaz-Torné C, Perez-Herrero N, Perez-Ruiz F. New medications in development for the treatment of hyperuricemia of gout. Curr Opin Rheumatol. 2015 Mar;27(2):164-9. doi: 10.1097/BOR.0000000000000146. Review. PubMed PMID: 25603039.